Alzheimer's drug that can slow disease gets backing from FDA advisers

FDA advisers unanimously voted for Eli Lilly's Alzheimer's drug as effective, outweighing risks like brain swelling. Final FDA approval pending.

Panelists acknowledge the drug could slow cognitive decline, though the detectable impact by patients or families remains uncertain.

Debate arose over the necessity of screening for tau protein before treatment, some arguing broad prescription without imaging is appropriate.

Read at ABC7 San Francisco